nartograstim

Nartograstim is a recombinant human granulocyte colony-stimulating factor (G-CSF) developed for hematopoietic therapy. It functions by mimicking natural human G-CSF, binding to G-CSF receptors on hematopoietic cells to stimulate the proliferation, differentiation, and functional activity of neutrophil precursors within the bone marrow. This action leads to an increased production and release of neutrophils, a type of white blood cell crucial for combating infections. Nartograstim is indicated for use in patients undergoing chemotherapy, those with severe chronic neutropenia, and individuals receiving bone marrow transplants to boost white blood cell counts and reduce the risk of infection. It is classified as a biologic medication.

Brand names

NeutroginGranocyte

Other names

MarograstimNoyapG-CSF, N-Met-Ala(1)-Thr(3)-Tyr(4)-Arg(5)-Ser(17)-G-CSF, N-methionyl-alanyl(1)-threonyl(3)-tyrosyl(4)-arginyl(5)-seryl(17)-granulocyte-colony-stimulating factor, N-Met-Ala(1)-Thr(3)-Tyr(4)-Arg(5)-Ser(17)-Nartograstim (genetical recombination)N-L-methionyl-1-L-alanine-3-L-threonine-4-L-tyrosine-5-L-arginine-17-L-serine-CSFN-L-methionyl1-L-alanine-3-L-threonine-4-L-tyrosine-5-L-arginine-17-L-serine-CSFN-L-methionyl 1-L-alanine-3-L-threonine-4-L-tyrosine-5-L-arginine-17-L-serine-CSFCOLONY-STIMULATING FACTOR (HUMAN CLONE 1034), 1-(N-L-METHIONYL-L-ALANINE)-3-L-THREONINE-4-L-TYROSINE-5-L-ARGININE-17-L-SERINE-GRANULOCYTE COLONY-STIMULATING FACTOR NARTOGRASTIM [MI]